Zhejiang Huahai Pharmaceutical (SHA:600521) will see 54 products and 79 specifications included in China's national essential medicines list in 2026, according to a Saturday filing with the Shenzhen bourse.
Among them, 23 products and its 33 specifications are additions to the list, including compound methoxyphenamine capsules and levetiracetam oral solution produced by subsidiary Changxing Pharmaceutical.